Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends

INTRODUCTION: Concerns of the persistence and severity of the adverse effects of fluoroquinolones, mainly involving the nervous system, muscles and joints, resulted in the 2018 referral procedure led by the European Medicines Agency (EMA). They advised to stop prescribing fluoroquinolones for infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Ly, Nelly F., Flach, Clare, Lysen, Thom S., Markov, Emanuil, van Ballegooijen, Hanne, Rijnbeek, Peter, Duarte-Salles, Talita, Reyes, Carlen, John, Luis H., Karimi, Leila, Reich, Christian, Salek, Sam, Layton, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044099/
https://www.ncbi.nlm.nih.gov/pubmed/36976448
http://dx.doi.org/10.1007/s40264-023-01286-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044099/
https://www.ncbi.nlm.nih.gov/pubmed/36976448
http://dx.doi.org/10.1007/s40264-023-01286-4

Ejemplares similares